HilleVax, Inc. (HLVX)
- Previous Close
12.53 - Open
12.49 - Bid 11.78 x 100
- Ask 11.97 x 100
- Day's Range
11.80 - 12.55 - 52 Week Range
9.94 - 20.22 - Volume
1,130,638 - Avg. Volume
147,100 - Market Cap (intraday)
589.451M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-3.04 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
29.00
HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.
www.hillevax.comRecent News: HLVX
Performance Overview: HLVX
Trailing total returns as of 4/18/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: HLVX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: HLVX
Valuation Measures
Market Cap
589.45M
Enterprise Value
337.16M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
2.22
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-2.83
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-25.19%
Return on Equity (ttm)
-46.39%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-123.57M
Diluted EPS (ttm)
-3.04
Balance Sheet and Cash Flow
Total Cash (mrq)
303.48M
Total Debt/Equity (mrq)
19.28%
Levered Free Cash Flow (ttm)
-62.11M
Research Analysis: HLVX
Analyst Price Targets
Fair Value
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell